Cystic fibrosis drug combo put to the test with statins

NCT ID NCT07349394

Completed Knowledge-focused Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested how a cystic fibrosis drug combo (vanzacaftor/tezacaftor/deutivacaftor) affects the body's processing of the statin rosuvastatin. 18 healthy adults took both medications to check for interactions and safety. The goal was to see if the drug combo changes rosuvastatin levels in the blood, which could guide future dosing for people with cystic fibrosis who also need statins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vanzacaftor/Tezacaftor/Deutivacaftor (a triple combination drug for cystic fibrosis)
What this could lead to: If successful, this study could help doctors understand how to safely combine this cystic fibrosis treatment with common statins like rosuvastatin.
What could go wrong: This is a very early, small study in healthy people, not patients. It only checks drug interactions, not whether the treatment works for cystic fibrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

Altasciences - Kansas City

Overland Park, Kansas, 66212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.